A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 microgram and 5 microgram) administered once daily in the afternoon via Respimat Inhaler for 12 weeks in patients 1 to 5 years old with persistent asthma

Trial Profile

A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 microgram and 5 microgram) administered once daily in the afternoon via Respimat Inhaler for 12 weeks in patients 1 to 5 years old with persistent asthma

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms NinoTinA-asthma
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results of pooled data analysis of 10 phase III studies (NinoTinA-asthma, CanoTinA-asthma,VivaTinA-asthma, RubaTinA-asthma,PensieTinA-asthma,GraziaTinA-asthma,MezzoTinA-asthma,PrimoTinA-asthma) assessing safety and tolerability presented at the 113th International Conference of the American Thoracic Society.
    • 06 Sep 2016 According to a Boehringer Ingelheim media release, safety data of this trial were presented at the European Respiratory Society (ERS) International Congress 2016.
    • 11 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top